These mutations result in a heterozygous and amplified allele that activates the Ras/Raf/MEK and PI3K/AKT pathways, with critical roles in predicting the prognosis, pathogenesis, progression and oncogenic behavior of NSCLC [42,43]. Here, MAP2K7 is linked to non-small cell lung carcinoma.